Holders — by stockHoldings — by fund
TCG Crossover Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001839948
$4.16B
disclosed book value
54
positions
19.2%
largest position share
Positions, as of 2026-06-30
top 54 of 54 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ABVXABIVAX SA AMERICAN DEPOSITARY SHARES | 6.0M | $800.6M | 19.2% |
| 2 | TNGXTANGO THERAPEUTICS INC | 9.1M | $283.9M | 6.8% |
| 3 | CGONCG ONCOLOGY INC | 3.7M | $260.8M | 6.3% |
| 4 | COGTCOGENT BIOSCIENCES INC | 4.9M | $187.9M | 4.5% |
| 5 | IMVTIMMUNOVANT INC | 4.5M | $171.8M | 4.1% |
| 6 | SYRESPYRE THERAPEUTICS INC | 1.9M | $168.7M | 4.1% |
| 7 | DNTHDIANTHUS THERAPEUTICS INC | 1.7M | $163.4M | 3.9% |
| 8 | MIRMMIRUM PHARMACEUTICALS INC | 1.1M | $124.3M | 3% |
| 9 | ZLABZAI LAB LTD-ADR | 6.1M | $116.6M | 2.8% |
| 10 | AMLXAMYLYX PHARMACEUTICALS INC | 6.2M | $112.1M | 2.7% |
| 11 | GLUEMONTE ROSA THERAPEUTICS INC | 4.6M | $111.9M | 2.7% |
| 12 | BCRXBIOCRYST PHARMACEUTICALS INC | 11.0M | $110.2M | 2.6% |
| 13 | VORVOR BIOPHARMA INC | 5.7M | $104.4M | 2.5% |
| 14 | TYRATYRA BIOSCIENCES INC | 3.2M | $103.8M | 2.5% |
| 15 | DYNDYNE THERAPEUTICS INC | 4.6M | $102.5M | 2.5% |
| 16 | IRONDISC MEDICINE INC | 1.3M | $98.1M | 2.4% |
| 17 | RLAYRELAY THERAPEUTICS INC | 4.3M | $80.0M | 1.9% |
| 18 | SVRASAVARA INC | 12.4M | $76.2M | 1.8% |
| 19 | AURAAURA BIOSCIENCES INC | 9.5M | $67.7M | 1.6% |
| 20 | RVMDREVOLUTION MEDICINES INC | 340,899 | $63.8M | 1.5% |
| 21 | TRAXFIRST TRACKS BIOTHERAPEUTICS | 2.9M | $58.3M | 1.4% |
| 22 | KODKODIAK SCIENCES INC | 1.4M | $56.3M | 1.4% |
| 23 | AVTXAVALO THERAPEUTICS INC | 3.0M | $55.8M | 1.3% |
| 24 | LBRXLB PHARMACEUTICALS INC | 1.4M | $47.0M | 1.1% |
| 25 | IPSCCENTURY THERAPEUTICS INC | 17.8M | $43.4M | 1% |
| 26 | TECXTECTONIC THERAPEUTIC INC | 1.2M | $41.4M | 1% |
| 27 | XNCRXENCOR INC | 2.5M | $39.5M | 0.9% |
| 28 | SRZNSURROZEN INC | 1.5M | $38.2M | 0.9% |
| 29 | EDITEDITAS MEDICINE INC | 11.1M | $36.0M | 0.9% |
| 30 | MBXMBX BIOSCIENCES INC | 650,000 | $35.9M | 0.9% |
| 31 | PHARVARIS BV | 1.0M | $34.9M | 0.8% |
| 32 | SLNSILENCE THERAPEUTICS PLC | 3.0M | $33.3M | 0.8% |
| 33 | INFLARX N V | 14.5M | $32.5M | 0.8% |
| 34 | ALTALTIMMUNE INC | 10.0M | $30.4M | 0.7% |
| 35 | JANXJANUX THERAPEUTICS INC | 1.8M | $27.5M | 0.7% |
| 36 | CATXPERSPECTIVE THERAPEUTICS INC | 7.9M | $27.0M | 0.6% |
| 37 | AGMBAGOMAB THERAPEUTICS NV | 2.1M | $26.7M | 0.6% |
| 38 | BIOHAVEN LTD | 1.8M | $26.5M | 0.6% |
| 39 | AKTSAKTIS ONCOLOGY INC | 696,560 | $22.5M | 0.5% |
| 40 | ALECALECTOR INC | 10.0M | $20.1M | 0.5% |
| 41 | FBRXFORTE BIOSCIENCES INC | 920,000 | $19.6M | 0.5% |
| 42 | MNPRMONOPAR THERAPEUTICS INC | 203,327 | $18.8M | 0.5% |
| 43 | OCULOCULAR THERAPEUTIX INC | 1.6M | $16.2M | 0.4% |
| 44 | ADC THERAPEUTICS SA | 11.4M | $12.2M | 0.3% |
| 45 | ALXOALX ONCOLOGY HOLDINGS INC | 5.7M | $11.7M | 0.3% |
| 46 | TRDAENTRADA THERAPEUTICS INC | 1.1M | $7.8M | 0.2% |
| 47 | CGEMCULLINAN THERAPEUTICS INC | 406,786 | $7.4M | 0.2% |
| 48 | ARVNARVINAS HOLDING CO LLC | 707,098 | $5.9M | 0.1% |
| 49 | KRROKORRO BIO INC | 416,301 | $5.5M | 0.1% |
| 50 | RESEARCH ALLIANCE CORP CL A | 500,000 | $5.3M | 0.1% |
| 51 | LONALEONABIO INC | 464,398 | $4.3M | 0.1% |
| 52 | JATT II ACQUISITION CORP | 200,000 | $2.3M | 0.1% |
| 53 | CNTXCONTEXT THERAPEUTICS INC | 2.7M | $1.5M | 0% |
| 54 | EIKNEIKON THERAPEUTICS INC | 37,902 | $494,621 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.